Ruhoys first book, Please Support Health Rising and Keep the Information Flowing A large Veterans Administration study, published in March 2025, which followed over 1,000,000 people, including 200,000 diabetic patients, found that GLP-1 agonists (semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), or exenatide (Byetta)) helped in a remarkably wide variety of ways
That makes it an off-label use, and legally and medically unsupported
Schedule your free consultation with a TrimBody M.D
As with US users, these findings reflect a retreat from both social drinking and convenience culture
gasseri: rather than primarily modulating fat absorption, L
Some studies reported metal concentrations exceeding safe daily intake limits by over 100% [33]